RobertCQuackenbushMD

Oncology • Walla Walla, WA

Physician

Join to view full profile

Dr. Quackenbush is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Quackenbush's full profile

Already have an account?

Office
401 W Poplar St
Walla Walla, WA 99362
Phone+1 509-522-5700

Fax+1 509-522-5705

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1992 - 1994
Washington University in St. Louis School of MedicineClass of 1992

Certifications & Licensure

ID State Medical License 2003 - 2025
OR State Medical License 2004 - 2025
WA State Medical License 2001 - 2025
TX State Medical License 1999 - 2002
NC State Medical License 1992 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3

Publications & Presentations

PubMed

8 citations
Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab.
Robert C. Quackenbush, Thierry Horner, Vanessa C. Williams, Patricia Giampietro, Thomas S. Lin
Leukemia & Lymphoma. 2015-03-01
50 citations
Neutrophilic-chronic myeloid leukemia: Low levels of p230 BCR/ABL mRNA and undetectable p230 BCR/ABL protein may predict an indolent course
Srdan Verstovsek, Hui Lin, Hagop Kantarjian, Giuseppe Saglio, Daniela De Micheli
Cancer. 2002-05-01
43 citations
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Robert C. Quackenbush, Gary W. Reuther, Juli P. Miller, Kevin D. Courtney, Warren S. Pear
Blood. 2000-05-01

Professional Memberships

American College of Physicians - ACP
Member